New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
NCT ID NCT07042802
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tests a new drug called LBL-024 combined with the chemotherapy paclitaxel in people with ovarian cancer that has become resistant to platinum-based treatments. The trial involves 110 participants and aims to see if the combination can shrink tumors and delay disease progression. It is an early-phase study, so the main goals are to check safety and get an initial read on effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LBL-024 and paclitaxel
- What this could lead to
- If it works, this could offer a new treatment option for people with ovarian cancer that has stopped responding to platinum-based chemotherapy.
- What could go wrong
- This is an early-phase trial with only 110 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AnYang Tumor Hospital
RECRUITINGAnyang, Henan, 455000, China
-
Beijing Obstetrics and Gynecology Hospital Capital Medical University
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100026, China
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
-
Fujian Cancer Hospital
NOT_YET_RECRUITINGFuzhou, Fujian, 350014, China
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510060, China
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221006, China
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, 450052, China
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
-
Tianjin Medical University Cancer Institute &Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
Yunnan Cancer Hospital
RECRUITINGKunming, Yunnan, 650106, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?